Tomer El-Gad

Title: The Innovations of Tomer El-Gad

Introduction

Tomer El-Gad is a notable inventor based in Rehovot, Israel. He has made significant contributions to the field of pharmaceuticals, particularly in the development of formulations for treating multiple sclerosis. With a total of five patents to his name, El-Gad's work is recognized for its innovative approaches to medication administration.

Latest Patents

Among his latest patents is a reduced volume formulation of glatiramer acetate and methods of administration. This invention focuses on a method for reducing the frequency of relapses in patients afflicted with relapsing-remitting multiple sclerosis (RRMS). The method involves administering 0.5 ml of an aqueous pharmaceutical solution containing 20 mg of glatiramer acetate and 20 mg of mannitol. Another significant patent by El-Gad is an improved injection assisting device. This device features an injection lock indicator designed to inform users whether the injection locking member is in a locked state. The indicator is configured to contrast in color with the device's outer shells, enhancing usability and safety.

Career Highlights

Tomer El-Gad is currently associated with Teva Pharmaceutical Industries Limited, a leading global pharmaceutical company. His work at Teva has allowed him to focus on innovative solutions that improve patient outcomes and streamline medication delivery.

Collaborations

El-Gad has collaborated with several professionals in his field, including Ayelet Altman and Doris Saltkill. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Tomer El-Gad's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare solutions. His patents reflect a deep understanding of patient needs and a drive to enhance treatment efficacy.